Beacon Quest designed with affordable two-chip
optofluidic system to accelerate the pace of scientific discovery
across academic, non-profit, and government research including
comprehensive single T Cell profiling, for precision immunotherapy
translational research and accelerated development
EMERYVILLE, Calif., June 5, 2023
/PRNewswire/ -- PhenomeX Inc. (Nasdaq: CELL), the functional cell
biology company, today announced the launch of the Beacon
Quest™ optofluidic system, with Opto® T Cell
Profiling workflows for immunotherapy translational
research and a platform price under $1
million USD, less than half of the higher-throughput Beacon
system, enabling broader accessibility to the cutting-edge
technology critical for next-generation precision medicine.
The Opto T Cell Profiling workflows have enabled scientists to
comprehensively profile single T cells to correlate
polyfunctionality with cytotoxicity and recover those same cells
for downstream analysis such as transcriptome and genome
sequencing, revealing functional connections of phenotype with
molecular mechanism. This depth of understanding of biology and
response to therapeutics is not available on any other platform.
Combined with the value-matched Beacon Quest system, more academic,
non-profit, and government customers can now access the power of
optofluidic and NanoPen® chamber technology and
propriety single T Cell Profiling applications along with the
optimum level of features to meet their research and budgetary
needs.
"At PhenomeX, we are excited to launch the Beacon Quest, as it
supports our objective of offering scientists and researchers
globally the ability to affordably access the main applications of
the Beacon system, including antibody discovery, cell line
development and single-cell functional multiomic T-cell profiling,"
said Siddhartha Kadia, Ph.D., chief executive officer of PhenomeX.
"We look forward to partnering with and providing significant value
in the academic research segments, particularly in immuno-oncology
translational cancer centers and innovative cell and gene therapy
development centers."
Beacon Quest for T Cell Profiling Workflow Features
Opto T Cell Profiling workflows on the Beacon Quest system enable
multi-functional characterization of single T cells,
including for development of efficacious immunotherapies and
cell-based cancer therapeutics, that are ideally suited for
academic, non-profit, and government customers.
The Beacon Quest system enables a variety of assays to profile
single T cells including detection of cytokine secretion,
cytotoxicity, cell surface markers, transcriptome profiling and
TCRSeq, with the potential to study growth characteristics and cell
motility. The resulting analysis is used to identify cells with
phenotypes of interest and guide recovery of the same cells for
downstream assays, enabling researchers to gain a deeper
understanding of the underlying biology by:
- Investigating molecular mechanisms associated with
polyfunctional T cells;
- Identifying desirable phenomes by correlating polyfunctionality
with cytotoxicity; and
- Linking desirable phenotypes to T cell receptor sequences of
the same cells.
In addition to supporting the Opto T Cell Profiling workflows,
Beacon Quest will enable customers to access the Opto B Discovery
workflows and Opto Cell Line Development workflows. To further
increase customer accessibility and affordability, PhenomeX will
also offer reduced priced OptoSelect® chips
(OptoSelect® Research chips) for Beacon Quest, helping
academic customers accelerate the pace of scientific discovery for
clinical research use applications.
About PhenomeX Inc.
PhenomeX is empowering scientists to leverage the full potential
of each cell and drive the next era of functional
cell biology that will advance human health. We enable
scientists to reveal the most complete insights on cell function
and obtain a full view of the behavior of each cell. Our unique
suite of proven high-throughput tools and services offer
unparalleled resolution and speed, accelerating the insights that
are key to advancing discoveries that can profoundly improve the
prevention and treatment of disease. Our award-winning
platforms are used by researchers across the globe, including those
at the top 15 global pharmaceutical companies and approximately 85%
of leading U.S. comprehensive cancer centers.
Forward-Looking Statements
To the extent that
statements contained in this press release are not descriptions of
historical facts regarding PhenomeX or its products, they are
forward-looking statements reflecting the current beliefs and
expectations of management. Such forward-looking statements involve
substantial known and unknown risks and uncertainties that relate
to future events, and actual results and product performance could
differ significantly from those expressed or implied by the
forward-looking statements. PhenomeX undertakes no obligation to
update or revise any forward-looking statements. For a further
description of the risks and uncertainties relating to the
Company's growth and continual evolution see the statements in the
"Risk Factors" sections, and elsewhere, in our filings with the
U.S. Securities and Exchange Commission.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/phenomex-launches-beacon-quest-optofluidic-system-with-opto-t-cell-profiling-workflows-301842270.html
SOURCE PhenomeX